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Abstract
Background: Centromere protein A (CENP-A) plays important roles in cell-cycle regulation and genetic stability. Herein, we
aimed to investigate its expression pattern, clinical significance, and biological function in hepatocellular carcinoma (HCC).
Methodology/Principal Findings: CENP-A expression at the mRNA and protein levels was examined in 20 pairs of fresh
HCCs and corresponding nontumor liver tissues. Immunohistochemistry for CENP-A was performed on 80 paraffin-
embedded HCC specimens, and the clinical significance of its expression was analyzed. A human HCC cell line HepG2 with
high abundance of CENP-A was used to study the effects of manipulating CENP-A on HCC growth. Quantitative real-time
polymerase chain reaction arrays and Western blot analysis were employed to identify the cell-cycle control- and apoptosis-
related genes regulated by CENP-A. The results showed that CENP-A was aberrantly overexpressed in HCCs relative to
adjacent nontumor tissues. This overexpression was significantly associated with positive serum HBsAg status, increased
histological grade, high Ki-67 index and P53 immunopositivity. Knockdown of CENP-A in HepG2 cells reduced cell
proliferation, blocked cell cycle at the G1 phase, and increased apoptosis. The antiproliferative effects of CENP-A silencing
were also observed in vivo. Conversely, CENP-A overexpression promoted HCC cell growth and reduced apoptosis.
Furthermore, many genes implicated in cell-cycle regulation and apoptosis, including CHK2, P21waf1, P27 Kip1, SKP2, cyclin
G1, MDM2, Bcl-2, and Bax, were deregulated by manipulating CENP-A.
Conclusions/Significance: Overexpression of CENP-A is frequently observed in HCC. Targeting CENP-A can inhibit HCC
growth, likely through the regulation of a large number genes involved in cell-cycle progression and apoptosis, and thereby
represents a potential therapeutic strategy for this malignancy.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
malignancies in the world, with a particularly high incidence in
Asian countries [1,2]. Epidemiological studies reveal that chronic
hepatitis B and C viral infection, chronic alcohol consumption,
and ingestion of aflatoxin B1-contaminated food are important
aetiological factors of HCC [1,3]. Although a wide range of
genetic and epigenetic alterations have been identified contribut-
ing to the deregulation of key oncogenes and tumor-suppressor
genes, genetic events in hepatic carcinogenesis are poorly
understood [1,2].
Genome stability relies on the accurate partitioning of
chromosomes into the daughter cells during division. Centromeres
are the chromatin regions associated with kinetochores, which
mediate chromosome segregation and the mitotic checkpoint
[4–6]. The kinetochore is assembled specifically during mitosis on
a specialized region of each chromosome called the centromere,
which is constitutively bound by .15 centromere-specific proteins
[7–9]. Centromere protein (CENP)-A, a centromere-specific 17-
kDa protein, is one of the first identified kinetochore components
in humans. It is a unique histone H3-like protein only found in
active centromeres and believed to be a central element in the
epigenetic maintenance of centromere identity [9–15]. CENP-A is
well conserved among eukaryotes; loss of its function due to
mutations or deletions results in chromosome missegregation,
suggesting its requirement for the maintenance of genetic stability
[16–18]. Accumulating evidence indicates that CENP-A and other
centromere proteins are frequently upregulated in cancers and
their overexpression is associated with the development of
aneuploidy, a hallmark of malignant cells [16,19–23]. Blocking
CENP-H expression using RNA interference (RNAi) technology
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doubling time [24]. CENP-E silencing in HeLa cells leads to
missegregation of chromosomes after a mitotic delay and produces
aneuploid daughter cells [25]. These observations suggest that the
aberrant expression of the CENP family members may be closely
linked to carcinogenesis.
Our previous works have shown that CENP-A was overex-
pressed in HCC [26], and RNAi-mediated depletion of CENP-A
in one HCC cell line HepG2 caused a cell cycle arrest at the G1
phase [27]. In the present study, we aimed to confirm the effects of
manipulating CENP-A on HCC growth and to clarify the
underlying molecular mechanism for CENP-A action. Addition-
ally, the clinical significance of CENP-A expression in HCC was
evaluated.
Results
Overexpression of CENP-A in human HCC cell lines and
tumor tissues
Analysis of CENP-A transcript using a real-time quantitative
polymerase chain reaction (qPCR) assay showed that HepG2 cells
expressed a significantly higher level of CENP-A mRNA than did
another HCC cell line SMMC-7721 (P,0.01; Figure 1A).
Western blotting analysis further revealed that the CENP-A
protein level was significantly higher in HepG2 cells compared to
that in SMMC-7721 (P,0.01; Figure 1B). Given the high
abundance of endogenous CENP-A, HepG2 cells were used in
the following knockdown experiments. We also examined the
expression of CENP-A in 20 pairs of snap-frozen HCC and
adjacent nonmalignant liver tissues. The CENP-A mRNA and
protein levels were significantly (P,0.01) elevated in HCC
specimens compared to the corresponding nontumor tissues, as
shown in Figure 1C&1D, respectively.
Associations between CENP-A expression and
clinicopathologic parameters of HCC patients
Immunohistochemistry using anti-CENP-A antibody was per-
formed on a set of 80 pairs of paraffin-embedded human HCC
specimens and adjacent nontumorous liver tissues. A low
frequency of the surrounding nontumorous tissues (35/80, 44%)
displayed rare positive nuclei (Figure 2A), while a markedly higher
proportion of HCC samples (57/80, 71%) showed positive CENP-
A immunostaining (Figure 2B–D). Expression of CENP-A
appeared to increase with the grades of differentiation of HCC
Figure 1. CENP-A mRNA and protein expression in HCC cell lines and tumor tissues. A: RT-PCR (left) and qPCR (right) analysis of CENP-A
mRNA expression in two HCC cell lines HepG2 and SMMC-7721. B: Western blotting analysis of CENP-A protein product in HepG2 and SMMC-7721
cells. Left: Representative Western blots of three independent experiments. Right: Quantification of the CENP-A Western blots. C: RT-PCR (upper) and
qPCR (lower) analysis of CENP-A transcript in HCC tumor (T) and corresponding nontumorous (N) liver tissues. D: Western blotting analysis of CENP-A
protein expression in HCC and adjacent nontumor tissues. The bar graph below the Western blot panels shows the quantification of the protein level
of CENP-A. GAPDH was used as an internal control in all the experiments.
**P,0.01 using Student’s t-test; n=3 in A and B, and n=20 in C and D.
doi:10.1371/journal.pone.0017794.g001
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D). Moreover, the CENP-A immunostaining pattern varied
among the tumors with different degree of differentiation. Well-
and moderately-differentiated HCC cells had an exclusive nuclear
staining pattern for CENP-A (Figure 2B&2C), while poorly-
differentiated cells displayed a mixed staining pattern, with intense
nuclear staining and weak, diffuse cytoplasmic staining (Figure 2D).
Next, we investigated the relationship between CENP-A
expression and clinicopathologic parameters of HCC patients. As
shown in Table 1, a higher frequency of CENP-A overexpression
was found in serum HBsAg positive patients (44/65, 68%) than in
negative ones (2/15, 13%; P=0.014). There was an increasing
tendency for CENP-A expression with the progression of histolog-
ical grade (P=0.017, I versus II; P=0.021, I versus III; P=0.004, I
versus IV). Additionally, CENP-A expression was positively
correlated with the Ki-67 staining index that was defined as the
percentage of Ki-67 immunopositive cells (r=0.685, P,0.001).
There was a significant relationship between CENP-A and P53 at
the protein level (r=0.72, P,0.001), but no correlation was noticed
between CENP-A and P21waf1 protein levels.
Alteration of CENP-A expression affects cell growth and
apoptosis of HepG2 cells
To elucidate the biological function of CENP-A in HCC, we
overexpressed and knocked down this gene in HepG2 cells. The
delivery of CENP-A-expressing constructs (pcDNA3.0-CENP-A)
resulted in a significant elevation in CENP-A expression at both
mRNA and protein levels, as compared to the control cells
transfected with pcDNA3.0 empty vector (P,0.01; Figure 3A&3B).
Conversely, the stable transfection of CENP-A small interfering
RNAs (siRNAs) significantly diminished the endogenous CENP-A
expression levels of HepG2 cells (P,0.01 versus mock transfectants;
Figure 3C&3D). The CENP-A1 siRNA appeared to be more efficient
in targeting CENP-A than CENP-A2, resulting in a reduction by
more than 70% in the CENP-A mRNA and protein amounts.
When compared to the pcDNA3.0 control cells, CENP-A
overexpression significantly increased cell proliferation assessed by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (P,0.05; Figure 4A). Colony formation assay
revealed a markedly increased colony number and size by the
overexpression of CENP-A (Figure 4B). A promotion of the cell
cycle from the G0/G1 to S phase was observed in the pcDNA3.0-
CENP-A cells (Figure 4C &4E). Moreover, apoptosis analysis
using annexin V and propidium iodide (PI) staining showed that
the pcDNA3.0-CENP-A cells had a significantly lower apoptotic
index than the pcDNA3.0 control cells (2.4160.86% versus
7.1761.14%, P,0.01; Figure 4D &4E). Converse to CENP-A
overexpression, its depletion by siRNAs significantly (P,0.05)
inhibited cell proliferation and colony formation compared to the
pSil2.1-U6 mock transfectants (Figure 4A&4B). Moreover, CENP-
A silencing caused a cell cycle arrest at the G1 phase and a
significant increase in apoptosis (P,0.01 compared to the pSil2.1-
U6 transfectants; Figure 4C–E).
Effects of manipulating CENP-A on tumor growth in a
HepG2 xenograft model
Next, we checked whether manipulating CENP-A affected
tumor growth in vivo, using a HepG2 xenograft model.
Figure 2. Immunohistochemistry for CENP-A in HCC and adjacent nontumor liver tissues. Representative CENP-A staining in (A)
nontumorous liver tissue, and in (B) well-differentiated, (C) moderately-differentiated, and (D) poorly-differentiated HCC. The CENP-A staining is
predominantly nuclear in the samples examined, with concurrent diffuse cytoplasmic staining in poorly-differentiated HCC.
doi:10.1371/journal.pone.0017794.g002
CENP-A in Hepatocellular Carcinoma
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17794Measurement of tumor volumes showed that the cells overex-
pressing CENP-A formed significantly larger tumors than the
control cells with pcDNA3.0 empty vector (P,0.01;
Figure 5A&5B). Conversely, downregulation of CENP-A by
CENP-A1 resulted in a significant suppression of tumor growth
as compared with the delivery of the pSil2.1-U6 mock vector
(P,0.01). Immunohistochemistry for CENP-A confirmed in-
creased staining in the pcDNA3.0-CENP-A tumors compared
with pcDNA3.0 vector tumors (Figure 6C). The pSil2.1-CENP-A1
tumors, as expected, had reduced immunoreactivity for CENP-A
relative to the pSil2.1-U6 tumors. Most interestingly, the Ki-67
immunoreactivity varied in parallel with the alteration of CENP-A
staining; i.e., the Ki-67 staining index was elevated in the
pcDNA3.0-CENP-A tumors in comparison with the pcDNA3.0
tumors (92.25617.44% versus 82.74614.69%, P,0.05) and
lowered in the pSil2.1-CENP-A1 tumors relative to the pSil2.1-
U6 tumors (55.43615.26% versus 84.56613.57%, P,0.01).
These results collectively indicate an important role for CENP-A
in the regulation of HCC growth.
Modulation of the expression of cell growth and
apoptosis related genes by CENP-A in HepG2 cells
To get more insight into the mechanism of CENP-A action, we
employed a real-time PCR array to profile the expression of genes
involved in the cell-cycle regulation. The gene expression profiling
was analyzed in the pSil2.1-CENP-A1 and pSil2.1-U6 (control)
transfectants. Of the 92 genes examined (Supplementary Table
S1), 20 showed a .2-fold change in expression, 3 upregulated and
17 downregulated (Table 2). Interestingly, all the 3 upregulated
genes (i.e., CHK2, P21waf1, and P27 Kip1) are negative regulators
of cell cycle [28–30]. Among the most downregulated genes were
SKP2, RAD51, and CCNG1, whose function is related to cell-
cycle progression [31–33]. To confirm the findings using the real-
time PCR array, Western blot analysis was performed to check the
changes of protein levels. CHK2 and P21waf1 protein levels were
significantly increased by CENP-A silencing, while SKP2,
RAD51, and CCNG1 were decreased under the same condition
(P,0.01 versus the pSil2.1-U6-transfected cells; Figure 6A).
Additionally, CENP-A overexpression resulted in a significant
decrease in the CHK2 and P21waf1 protein levels and elevation in
the levels of SKP2, RAD51, and CCNG1 (P,0.01 versus the
transfection of pcDNA3.0). Taken together, the deregulation of
cell-cycle-related genes partially explains the CENP-A-depletion-
induced growth arrest.
The P53 pathway has been recognized to be important for cell-
cycle arrest and apoptosis [34]. We next examined some key
components of this pathway, including P53, MDM2 (an
endogenous inhibitor of P53 [35]), anti-apoptotic protein Bcl-2,
and pro-apoptotic protein Bax [36], in the HepG2 cells treated as
above. The protein levels of MDM2 and Bcl-2 were significantly
elevated by CENP-A overexpression (P,0.01; Figure 6B). An
opposing trend was observed for Bax expression in CENP-A-
overexpressing cells. In the setting of CENP-A silencing, MDM2
and Bcl-2 amounts were significantly lowered while Bax
expression was potentiated. However, no significant difference
was detected in the P53 protein level when the CENP-A level was
altered.
Discussion
In this study, we confirm and extend our previous findings [26]
that CENP-A expression is significantly elevated in HCC.
Moreover, the protein product of CENP-A is increased in parallel
with its transcript, suggesting that CENP-A overexpression occurs
at the transcriptional level. Clinical association analysis reveals that
CENP-A overexpression is positively correlated with the Ki-67
index and the tumor histological grade, implying its involvement
in HCC development. To dissect the function of CENP-A in
HCC, we employed gain- and loss-of-function approaches to assess
the effects of manipulating CENPA-A on cell growth and
apoptosis in HepG2 cells. Overexpression of CENP-A significantly
increased the cell proliferation and colony number in vitro, while
Table 1. Clinicopathologic significance of CENP-A
overexpression in HCC (n=80).
Variables No. CENP-A immunoreactivity P
Negative Low High
Sex
Male 61 19 8 34 0.190
Female 19 4 3 12
Age
Less than median 38 10 7 21 0.645
Greater than median 42 13 4 25
Serum AFP level (mg/l)
,20 38 9 6 23 0.517
$20 42 14 5 23
Serum HBsAg
Positive 65 17 4 44 0.014
Negative 15 6 7 2
Tumor size
#2 cm 28 8 5 15 0.553
.2c m 5 2 1 5 6 3 1
Histological grades
I1 0 7 2 1
II 34 9 8 17 0.017
III 28 7 0 21 0.021
IV 8 0 1 7 0.004
Liver cirrhosis
Absent 21 5 4 12 0.621
Present 59 18 7 34
Tumor capsule
Intact 20 7 4 9 0.193
Absent or not intact 60 16 7 37
Intrahepatic metastasis
Not observed 28 10 4 14 0.683
Observed 52 13 7 32
P53
Positive 60 6 54 ,0.001
Negative 20 17 3
Ki-67 index
$50% 43 0 43 ,0.001
,50% 37 23 14
P21
waf1
Positive 25 5 20
Negative 55 18 37 0.224
Total 80 23 11 46
doi:10.1371/journal.pone.0017794.t001
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decrease in cell growth. Using a HepG2 xenograft model in nude
mice, we found that manipulating CENP-A also significantly
affected tumor growth in vivo. These results highlight a crucial
role for CENP-A in the regulation of HCC growth.
CENP-A plays a central role in directing kinetochore assembly,
which is indispensable for equal chromosome segregation. Re ´gnier
and colleagues [17] have reported that CENP-A disruption
impairs kinetochore formation in the chicken DT40 cell line and
CENP-A-depleted cells proceed through anaphase and cytokinesis
with unequal chromosome segregation. By depleting the Dro-
sophila homolog of CENP-A, CID, Blower and colleagues [37]
showed that CID was required for normal kinetochore formation
and function, as well as cell-cycle progression. A recent study by
Maehara et al. [38] has indicated that CENP-A reduction in
primary human diploid lung fibroblasts induces a P53-dependent
cellular senescence, an irreversible growth arrest. Consistent with
the previous findings, our data demonstrate that RNAi-mediated
knockdown of CENP-A causes a cell cycle arrest at the G1 phase
and increases apoptosis in HepG2 cells. Converse to the inhibitory
effects of CENP-A depletion, overexpression of CENP-A signif-
icantly promotes cell-cycle progression and favors cell survival.
These results collectively suggest that aberrant expression of
CENP-A may be an important etiologic factor for the pathogenesis
of HCC. Indeed, CENP-A overexpression has been proposed to
contribute to the aneuploidy of tumors [17,39].
To clarify the molecular mechanism by which CENP-A affects
cell proliferation, we employed the real-time PCR array to profile
the expression of cell cycle-related genes. Three of the 20 genes
altered .2 fold were upregulated when the CENP-A expression
was knocked down. The 3 upregulated genes (CHK2, P21waf1,
and P27 Kip1) play a negative role in cell-cycle progression [28–
30]. The cyclin-dependent kinase (CDK) inhibitors P21waf1 and
P27 Kip1 can bind to and inhibit the activity of various cyclin-
CDK complexes, functioning as critical regulators of cell cycle at
the G1/S-phase transition [40,41]. Cell cycle checkpoint kinase 2
(CHK2) is known to inhibit CDC25C phosphatase and stabilize
the p53 tumor suppressor protein, leading to cell cycle arrest in G1
[42]. Most interestingly, CENP-A silencing induced a G1 arrest of
the cell cycle in HepG2 cells. These results suggest the
antiproliferative effects of targeting CENP-A are linked to the
upregulation of negative cell-cycle regulators including CHK2,
P21waf1, and P27 Kip1. However, we found no significant
relationship between CENP-A and P21waf1 in HCC samples by
immunohistochemistry, reflecting a complex regulation of gene
expression by CENP-A. Among the most downregulated genes by
CENP-A silencing are SKP2, RAD51, and CCNG1. SKP2 is of
particular interest, as it plays a key role in S-phase entry [43].
SKP2 has been shown to target P27 Kip1 and cyclin E for
degradation and control the cell cycle at the G1-S transition [44].
Taken together, our data indicate that CENP-A affects HCC cell
proliferation via the coordination of multiple positive and negative
regulators of cell-cycle progression.
The P53 pathway has been shown to mediate cellular stress
responses, inducing cell-cycle arrest, senescence, and apoptosis
[34]. Our clinical data indicate that there is a significant
correlation between CENP-A and P53 immunopositivity in
HCC. The involvement of the P53 pathway in CENP-A action
has been documented in a previous study [38], where P53 was
found to be essential for the CENP-A-depletion-induced cellular
senescence. To test whether the P53 pathway was involved in the
effects of CENP-A on HCC cell apoptosis, we examined the
expression of several key components of this pathway (i.e., P53,
MDM2, Bcl-2, and Bax) in the HepG2 cells overexpressing or
depleted CENP-A. The endogenous P53 inhibitor MDM2 and the
anti-apoptotic protein Bcl-2 protein amounts were significantly
elevated in CENP-A-overexpressing cells, while the expression of
the pro-apoptotic protein Bax was compromised under the same
condition. Conversely, silencing of CENP-A decreased the MDM2
and Bcl-2 protein levels but increased the Bax protein products.
However, no significant alteration in the P53 expression was
observed by manipulating CENP-A in HepG2 cells. These results
collectively suggest that targeting CENP-A can induce HCC cell
apoptosis, likely through a P53-independent pathway. A recent
study has demonstrated that genetic SKP2 inactivation suppresses
tumorigenesis by evoking a P53-independent cellular senescence
[45], raising the possibility that in at least some HCC cells, CENP-
A reduction promoted apoptosis through the inhibition of SKP2.
Further investigations are needed to test this hypothesis.
In summary, CENP-A is frequently overexpressed in HCC and
its overexpression correlates with tumor histological grade and P53
immunopositivity. RNAi-mediated CENP-A depletion suppresses
HCC cell growth both in vitro and in vivo, blocks cell-cycle
progression at the G1 phase, and promotes apoptosis. The
anticancer effects of depleting CENP-A are likely mediated
through the regulation of a large number of genes involved in
cell-cycle control and apoptosis, including CHK2, P21waf1, P27
Kip1, SKP2, MDM2, Bcl-2, and Bax. These data suggest that
CENP-A may be a potential therapeutic target for HCC.
Materials and Methods
Cell line and cell culture
HepG2 and SMMC-7721 cell lines (wild-type p53 and HBV
negative) were purchased from Institute of Cellular Research,
Chinese Academy of Science, Shanghai, China. Cells were
routinely cultured as previously described [46].
Human HCC samples
Tumor samples from resection specimens were collected from
two consecutive cohorts of patients with HCC. Cohort A consisted
of 20 patients, from whom fresh tumor samples coupled with
adjacent nontumor liver tissues were obtained for analysis of
CENP-A gene expression. After removal at surgery, all the fresh
tissues were cut into small pieces, snap-frozen in liquid nitrogen
immediately, and stored at 280uC until RNA or protein
extraction. Cohort B comprised 80 HCC patients, whose
paraffin-embedded tumor tissues represented on tissue micro-
arrays were analyzed by immunohistochemistry. All tissues were
obtained during surgeries in Changhai Hospital between August
Figure 3. CENP-A overexpression and knockdown in HepG2 cells. Analysis of CENP-A mRNA (A, C) and protein (B, D) levels in HepG2 cells
transfected with CENP-A-expressing plasmids or siRNA-expressing plasmids, as described in Materials and methods. A: RT-PCR (left) and qPCR (right)
measurement of CENP-A transcript in cells transfected with pcDNA3.0-CENP-A or pcDNA3.0 empty vector.
**P,0.01 using Student’s t-test; n=3.B,
left: Representative Western blots for CENP-A in cells treated as in A. Right: Quantification of the blotting shown in the left panel.
**P,0.01 using
Student’s t-test; n=3.C: RT-PCR (left) and qPCR (right) examination of CENP-A mRNA levels in HepG2 cells transfected with CENP-A1, CENP-A2, or
pSil2.1-U6 empty vector (control).
**P,0.01 compared to cells with the pSil2.1-U6, using one-way ANOVA; n=3.D: Immunoblot of cells treated as in
C. Left: Representative Western blots for CENP-A. Right: Quantification of the blotting shown in the left panel.
**P,0.01 compared to cells with the
pSil2.1-U6, using one-way ANOVA; n=3. GAPDH was used as an internal control in all the experiments.
doi:10.1371/journal.pone.0017794.g003
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expressing plasmids, siRNA-expressing plasmids, or empty vectors, as described in Materials and methods. The stable transfectants were subjected to
the following experiments. A: Cell proliferation assay. The HepG2 transfectants were seeded in 96-well microplates in sextuplicate and cultured for up
to 7 days. Cell proliferation was assessed by the MTT assay.
**P,0.01 between pSil2.1-U6 and pSil2.1-CENP-A1 or pSil2.1-CENP-A2;
#P,0.05 between
pcDNA3.0 and pcDNA3.0-CENP-A; n=3.B: Colony formation assay. The transfected or untreated HepG2 cells were plated in 6-well plates at a density
of 1,000 cells per well. After 10 days, cells were stained with Giemsa and colonies consisting of .50 cells were scored. Representative dishes of three
independent experiments are shown. C–E: Cell-cycle and apoptosis analysis. The transfected or untreated HepG2 cells were stained with PI alone or
FITC-annexin V and PI and analyzed by flow cytometry. Representative histograms (C) and dot plots (D) of three independent experiments are shown.
Apoptotic cells in D are FITC-annexin V positive and PI negative. E: Quantification of the cell-cycle and apoptosis analysis. The apoptotic index was
CENP-A in Hepatocellular Carcinoma
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from the Ethics Committee of Second Military Medical University.
The excised samples were obtained within one hour after the
operation from tumor tissues and the corresponding adjacent
nontumor tissues 5 to 10 cm from the tumor. The patients of both
cohorts were selected based on (a) distinctive pathologic diagnosis of
HCC according to the World Health Organization histological
classification of tumors of the liver and intrahepatic bile ducts (2000)
[47], (b) receiving curative resection, defined as macroscopically
complete removal of the neoplasm, and (c) availability of detailed
clinicopathologic data. Patients with preoperative anticancer
treatment or with evidence of other malignancies were excluded
from the study.Allpatients werenegative forserum HCVand HIV.
RNA isolation, reverse transcription-polymerase chain
reaction (RT-PCR), and qPCR
RT-PCR and qPCR analysis was performed as previously
described [48,49]. Briefly, total RNA was extracted from cells or
tissues with an RNeasy mini kit (Qiagen, Germany) according to
the manufacturer’s protocol. Complementary DNA (cDNA) was
synthesized from total RNA with the First-Strand cDNA Synthesis
Kit for RT-PCR (Roche, Mannheim, Germany). RT-PCR
amplification was achieved using Taq DNA Polymerase (Ampli-
Taq Gold; Roche Molecular Systems, Pleasanton, CA) at the
following conditions: one cycle at 94uC for 5 min, 30 cycles at
95uC for 30 sec, 58uC for 45 sec, and 72uC for 1.5 min, and one
cycle at 72uC for 10 min. CENP-A cDNA was amplified with
primers: forward 59-ACAAGGTTGGCTAAAGGA-39 and re-
verse 59-ATGCTTCTGCTGCCTCTT-39 (178 bp). For controls,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was ampli-
fied in a parallel reaction, with the following primers: 59-
TCCACCACCCTGTTGCTGTA-39 and 59-ACCACAGTC-
CATGCCATCAC-39 (452 bp). RT-PCR products were separat-
ed by electrophoresis on 1.5% agarose gels. The qPCR was
performed using SYBR-green detection of PCR products in real
time with the Light Cycler (Roche Diagnostics, Meylan, France).
The cycling conditions were as follows: initial denaturation at
95uC for 10 min, and then 45 cycles of denaturation at 95uC for
5 s, annealing at 62uC for 20 s, and elongation at 72uC for 15 s.
As an internal quantitative control, b-actin gene expression was
determined with the primers: 59-GAGCGGGAAATCGTGCGT-
GACATT-39 and 59-GATGGAGTTGAAGGTAGTTTCGTG-
39 (234 bp). Gene expression was analyzed using the Light Cycler
software Version 3.5 (Roche Diagnostics), and the ratios of CENP-
At ob-actin represented normalized relative levels of CENP-A
expression [50]. A no-template negative control was also included
in each experiment. Analyses of all samples were carried out in
triplicate, and the mean values were calculated.
Protein extraction and Western blotting analysis
Primary antibodies employed were: anti-CENP-A (ab13939,
Abcam, Cambridge, UK; 1:500), anti-GAPDH (Santa Cruz Biotech,
Santa Cruz, CA; 1:2000), anti-P53 (Do-1, sc-126, Santa Cruz
Biotech; 1:300), anti-P21waf1 (F-5, sc-6246, Santa Cruz Biotech;
1:200),anti-SKP2(F-5, sc-7163, Santa Cruz Biotech; 1:200),anti-Bcl-
2 (sc-7382,SantaCruz Biotech; 1:400), anti-Bax(sc-7480, Santa Cruz
Biotech; 1:300), anti-MDM2 (sc-965, Santa Cruz Biotech; 1:400),
anti-CHK2(ab47433, Abcam,Cambridge, UK; 1:500), anti-RAD51
(ab88572, Abcam, Cambridge, UK; 1:500), and anti-cyclin G.1(sc-
8016, Santa Cruz Biotech; 1:300). Protein isolation of culture cells or
tissues and Western blotting were carried out as previously described
[46]. Briefly, culture cells or tissues were lysed in buffer containing
10 mmol/L Tris (pH 7.4), 1% sodium dodecyl sulfate (SDS),
1 mmol/L sodium orthovanadate, and complete protease inhibitors
(Roche). The extraction was accomplished using the Klose method as
described previously [51,52]. Samples of the lysates (50 mg) were then
separated using SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to polyvinylidene fluoride membranes (Millipore,
Bedford, MA), and blotted with the primary antibodies. After the
incubation with horseradish peroxidase-conjugated secondary anti-
body (Santa Cruz Biotech), the blots were visualized with enhanced
chemiluminescence (sc-2048, Santa Cruz Biotech). The intensity of
each band was measured using a Fluor-S MultiImager and Quantity-
One software (Bio-Rad, Hercules, CA).
Immunohistochemistry
Immunohistochemistry was performed by SP-9000 Histos-
tainTM-plus kit (Zhongshan golden bridge Biotech, Beijing,
China) as previously described [46]. The primary antibodies
included anti-CENP-A (ab13939, Abcam; 1:100), anti-Ki-67
(MIB-1, DAKO, Glostrup, Denmark; 1:100), anti-P53 (Santa
Cruz Biotech; 1:50), and anti-P21waf1 (Santa Cruz Biotech; 1:40).
We defined that a less than 10% represented low, and more than
10% represented high levels of CENP-A and P21 waf1 expression
[49]. P53 staining was considered positive when more than 5%
nuclei of cells were immunopositive. The Ki-67 labeling index was
calculated as the percentage of immunopositive of cells.
Plasmid construction and transfection
Full-length human CENP-A (GenBank number: U14518) was
amplified by PCR and cloned into the pcDNA3.0 vector (Invitrogen,
Carlsbad, CA) for overexpression studies. The sequences of primers
for CENP-A were as follows: forward 59-GCTCTAGATCCCCA-
GAAGCCAGCCTTTC-39 and reverse 59-TAGAATTCCT-
CAGCCGAGTCCCTCCTCA-39. For knockdown of CENP-A
expression, three siRNAs were designed following the rules of Tuschl
[53]. The siRNA sequences were as follows: CENP-A1, 59-
AAAGGAGATCCGAAAGCTTCA-39 (corresponding to nucleo-
tides 144 to 164), CENP-A2, 59-AAATATGTGTTAAATT-
CACTC-39 (corresponding to nucleotides 218 to 238), and CENP-
A3, 59-AAGCATTTCTAGTTCATCTCTTT-39 (corresponding to
nucleotides 296 to 318). The siRNA oligonucleotides were
synthesized and inserted into the pSilencer 2.1-U6 vector (Ambion,
Inc., Austin, TX). The integrity of all the constructs was confirmed by
DNA sequencing. The plasmids were transfected into HepG2 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to
the manufacture’s protocol. The CENP-A1 and CENP-A2 siRNAs
with high knockdown efficiency were used for the subsequent
experiments. Stable transfectants were selected for 2 weeks in the
presence of G418 (400 mg/mL). HepG2 cells stably transfected with
CENP-A1 and CENP-A2 were named as pSil2.1-CENP-A1 and
pSil2.1-CENP-A2, respectively.
Proliferation assay
Transfected HepG2 cells were plated in 96-well microplates
(1.5610
3 cells per well and six repeats per cell line). Cells were
counted daily over a 7-day period by the CellTiter 96 Non-
Radioactive Cell Proliferation Assay (Promega, Madison, WI)
determined as the ratio of apoptotic cell number to total cell number.
#P,0.05,
##P,0.01, compared to the pcDNA3.0 empty vector;
*P,0.05,
**
P,0.01, compared to the pSil2.1-U6; n=3.
doi:10.1371/journal.pone.0017794.g004
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PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17794Figure 5. Effects of CENP-A overexpression or knockdown on tumorigenicity in nude mice. The transfected or untreated HepG2 cells
were injected into nude mice, as described in Materials and methods. Tumor volume was determined every 5 days for 30 days. At the end of the
experiment, animals were sacrificed and tumors were excised for volume measurement and histological study. A: Representative photographs of
tumors for each treatment. B: Growth curve of tumor xenografts.
##P,0.01, compared to the pcDNA3.0 empty vector;
**P,0.01, compared to the
pSil2.1-U6; n=4.C: The resected tumors were stained with HE and antibodies against Ki-67 and CENP-A. Representative images of the staining are
shown. The percentages of Ki-67-positive and CENP-A-positive cells were inserted in the corresponding images.
doi:10.1371/journal.pone.0017794.g005
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17794[46]. The dark-blue crystals of MTT-formazan were dissolved by
shaking the plates at room temperature for 10 min and the
absorbance was then measured on a Bio-Rad Microplate Reader
at a test wavelength of 490 nm and a reference wavelength of
630 nm. Each growth curve showed the means and standard
deviation (SD) of at least three independent experiments.
Colony formation
Detailed experimental procedures were as described previously
[46,54]. Briefly, transfected HepG2cellswere plated in six-wellplates
at a density of 1,000 cells per well in routine culture medium.After 10
days, cells were washed with PBS, fixed in 10% methanol for 15 min,
and stained in Giemsa for 20 min. Colonies consisting of .50 cells
were scored. Each experiment was repeated three times.
Cell cycle and apoptosis analysis
Cellular DNA content was analyzed by flow cytometry as
described previously [46]. Briefly, HepG2 transfectants in
logarithmic phase were harvested, fixed in ethanol, and incubated
with 0.5 mg/ml of propidium iodide (PI) along with 0.1 mg/ml of
RNase A (200 KU; Calbiochem, San Diego, CA), prior to cell-
cycle analysis. Apoptosis was measured with an Annexin V/FITC
kit (LHK601-100, Bender Medsystems, Austria) according to the
manufacturer’s protocol. Each assay was repeated three times.
Tumorigenicity in nude mice
The tumorigenicity assay was performed as previously described
[46]. Nude mice were purchased from the Experimental Animal
Center of Shanghai, Shanghai, China. They were randomly
divided into 4 groups (3 mice in each group), and were injected
subcutaneously at a single site with 2610
6 cells stably transfected
with pcDNA3.0-CENP-A, CENP-A1, or empty vectors or with
untreated HepG2 cells. All experimental manipulations were
undertaken in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, with the
approval of the Scientific Investigation Board of the Second
Figure 6. Alteration of gene expression profiling by CENP-A overexpression or knockdown in HepG2 cells. HepG2 cells were untreated
or transfected with CENP-A-expressing plasmids, siRNA-expressing plasmids, or empty vectors (pcDNA3.0, and pSil2.1-U6). Forty-eight hours after the
transfection, cells were subjected to Western blotting for the proteins indicated. A&B: Representative Western blots are shown in left panels. Right
panels show the quantification of the immunoblots.
#P,0.05,
##P,0.01, compared to the pcDNA3.0 empty vector;
** P,0.01, compared to the
pSil2.1-U6; n=3.
doi:10.1371/journal.pone.0017794.g006
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PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17794Military Medical University, Shanghai, China. The mice were
observed for 30 days for tumor formation and then sacrificed. The
tumors were harvested and verified as being hepatocellular
carcinoma by hematoxylin and eosin (HE) staining. The number
and diameter of tumors were measured.
RT
2 Profiler
TM PCR array
To profile the gene expression associated with cell-cycle
regulation, we employed the Human Cell Cycle RT
2 Profiler
TM
PCR Array (SuperArray, Frederick, MD). RNA isolation, DNase
treatment, and RNA clean-up were performed according to the
manufacturer’s protocol (Qiagen, Hilden, Germany). The isolated
RNA was reverse transcribed into cDNA using the RT
2 First
Strand Kit (Invitrogen). PCR was performed using the RT
2 SYBR
Green qPCR Master Mix (Invitrogen) on an ABI PRISM7900
instrument (Applied Biosystems, Foster City, CA). Data normal-
ization was based on correcting all Ct values for the average Ct
values of several constantly expressed housekeeping genes present
on the array [55]. The analysis was completed by Shanghai
KangChen Bio-tech Company, Shanghai, China. Each assay was
conducted in triplicate.
Statistical analysis
Data were presented as means6SD. All statistical calculations
were carried out using SPSS.11 software (SPSS, Chicago, IL). The
difference among the means of multiple groups was analyzed by
one-way analysis of variance (ANOVA) followed by the Tukey
test. A difference was defined as significant at P,0.05 in Student’s
t- test, one-way ANOVA, or Chi-square test. A correlation
coefficient .0.5 or ,20.5 was considered significant for Spear-
man’s correlation.
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Table S1 Positive and negative transcriptional regula-
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